Relative risk of cardiovascular events in patients with rheumatoid arthritis

American Journal of Cardiology

Volumn 89, Issue 6 SUPPL. 1, 2002, Pages 33-38

  DeMaria, Anthony N ^a  

^a UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; COMORBIDITY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SPECIFICITY; HUMAN; INCIDENCE; INFLAMMATION; MORTALITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; THROMBOGENESIS; THROMBOSIS; TREATMENT INDICATION;

EID: 0037149297     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)02235-X     Document Type: Article

References (63)

1. Prevalence of disability and associated health conditions
2. The prevalence of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study
3. Knee osteoarthritis and physical functioning: Evidence from the NHANES I Epidemiologic Followup Study
4. Comorbidity in arthritis
5. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis
6. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
7. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation
8. Roles of cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial cells: Selective up-regulation of prostacyclin synthesis by COX-2
9. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
10. The epidemiology of rheumatoid arthritis
11. Epidemiology of rheumatic diseases
12. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
13. Hormonal alterations in rheumatoid arthritis, including the effects of pregnancy
14. Comorbidity and lifestyle, reproductive factors, and environmental exposures associated with rheumatoid arthritis
15. The relationship between socioeconomic status and recently diagnosed rheumatoid arthritis
16. Formal education level as a significant marker of clinical status in rheumatoid arthritis
17. What happens to patients with rheumatoid arthritis? The long-term outcome of treatment
18. No increased mortality in patients with rheumatoid arthritis: Up to 10 years of follow up from disease onset
19. The mortality of rheumatoid arthritis
20. Mortality in rheumatoid arthritis
21. Mortality in rheumatoid arthritis
22. Total mortality is increased in rheumatoid arthritis. A 17-year prospective study
23. Survival study of rheumatoid arthritis patients in Madrid (Spain). A 9-year prospective follow-up
24. Comorbidity in rheumatoid arthritis
25. Cardiovascular mortality in patients with rheumatoid arthritis
26. Longterm mortality outcome in patients with rheumatoid arthritis: Early presenters continue to do well
27. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden
28. Cardiovascular mortality in women with rheumatoid arthritis
29. Cause of death in rheumatoid arthritis
30. Shortening of life span and causes of excess mortality in a population-based series of subjects with rheumatoid arthritis
31. Higher incidence of cardiovascular disease (CVD) with rheumatoid arthritis (RA) than osteoarthritis (OA) in the UK General Practice Research Database (GPRD)
32. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset
33. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: An 8 year followup study
34. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome
35. Radiographic outcome of recent-onset rheumatoid arthritis: A 19-year study of radiographic progression
36. Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: Longterm course and association to radiographic progression
37. C-reactive protein, cardiovascular risk factors and the association with myocardial infarction in men
38. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men
39. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
40. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
41. Direct proinflammatory effect of C-reactive protein on human endothelial cells
42. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina
43. Perturbation of the T-cell repertoire in patients with unstable angina
44. A tale of two diseases: Atherosclerosis and rheumatoid arthritis
45. Cyclooxygenase inhibition and thrombogenicity
46. NSAIDs and increased blood pressure. What is the clinical significance?
47. NSAIDs and blood pressure. Clinical importance for older patients
48. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis
49. The impact of nonsteroidal anti-inflammatory drugs on hypertension: Alternative analgesics for patients at risk
50. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An underrecognized public health problem
51. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
52. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study
53. The relationship between NSAIDs and myocardial infarction
54. Reduced risk of acute thromboembolic events with naproxen in rheumatoid arthritis patients in the UK General Practice Research Database (GPRD)
55. Association of conventional non-aspirin nonsteroidal antiinflammatory drugs (NSAIDs) with hospitalizations for myocardial infarction
56. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
57. Effect of short-term aspirin use on C-reactive protein
58. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women
59. AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: A statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association
60. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 Update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology